Haemonetics (STU:HAZ) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HAZ Haemonetics Corp STU:HAZ
30 GF Score
Price €68.00
GF Value €74.36
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Haemonetics FFO per Share?

FFO per Share only applies to REITs.

STU:HAZ
30GF Score
Haemonetics Corp STU:HAZ
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €68.00 is trading 8.6% below its estimated GF Value™ of €74.36. GuruFocus considers Haemonetics to be Fairly Valued.

Key valuation signals for STU:HAZ:

  • FFO per Share:
  • GF Value™: €74.36 vs. price of €68.00 (8.6% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
30GF Score

Get the complete analysis for STU:HAZ

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.00
Price
€74.36
GF Value